A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies

PURPOSE: UCN-01 (7-hydroxystaurosporine) is a multi-targeted protein kinase inhibitor that exhibits synergistic activity with DNA-damaging agents in preclinical studies. We conducted a Phase I study to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetic, and pha...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Fracasso, Paula M., Williams, Kerry J., Chen, Ronald C., Picus, Joel, Ma, Cynthia X., Ellis, Matthew J., Tan, Benjamin R., Pluard, Timothy J., Adkins, Douglas R., Naughton, Michael J., Rader, Janet S., Arquette, Matthew A., Fleshman, James W., Creekmore, Allison N., Goodner, Sherry A., Wright, Lisa P., Guo, Zhanfang, Ryan, Christine E., Tao, Yu, Soares, Eliane M., Cai, Shi-rong, Lin, Li, Dancey, Janet, Rudek, Michelle A., McLeod, Howard L., Piwnica-Worms, Helen
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Springer-Verlag 2010
Θέματα:
Original Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3102212/
https://ncbi.nlm.nih.gov/pubmed/20694727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-010-1410-1
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια